Listen in to the live broadcast at 10a PT, 11a MT, 12p CT, 1p ET 6p UK
“C. diff. Spores and More,”
Summit Therapeutics: ridinilazole, a microbiome preserving antibiotic for the treatment of a C. difficile infection (CDI)
With Our Guests:
Dr. Kevin W. Garey; Chair, Department of Pharmacy Practice and Translational Research Professor of Pharmacy Practice at the University of Houston College of Pharmacy, Houston, TX
Dr. Richard Vickers, Chief Scientific Officer at Summit Therapeutics
Join us as we discuss a promising and new treatment for a C. difficile infection. Summit Therapeutic’s Ridinilazole, a microbiome preserving antibiotic will be introduced with updates with our guests Dr. Kevin W. Garey, Chair, Department of Pharmacy Practice and Translational Research, Professor of Pharmacy Practice at the University of Houston College of Pharmacy, Houston, Texas and Dr. Richard Vickers, Chief Scientific Officer at Summit Therapeutics
“C. diff. Spores and More
Through their interviews, the C Diff Foundation mission will connect, educate, and empower many worldwide.
Questions received through the show page portal will be reviewed and addressed by the show’s Medical Correspondent, Dr. Fred Zar, MD, FACP, Dr. Fred Zar is a Professor of Clinical Medicine, Vice He
Clostridium difficile disease and the need to stratify patients by disease severity.
To access the C. diff. Spores and More program page and library, please click on the following link: www.voiceamerica.com/show/2441/c-diff-spores-and-more
Take our show on the go…………..download a mobile app today
Programming for C. diff. Spores and More